Nebraska AG Hilgers: Seeks Court Endorsement for Generic Drug Settlement

• Nebraska Attorney General Mike Hilgers is seeking court approval for three settlements.
• The settlements involve generic drug manufacturers Ascend Laboratories, Citron Pharma, and Mayne Pharma.
• These companies faced allegations of a widespread conspiracy to inflate prices and limit competition.
• Attorney General Hilgers joined a coalition of 45 states and territories in this action.
• The settlements aim to resolve generic drug price fixing antitrust claims.

Compliance officers in the pharmaceutical industry should review their antitrust policies and pricing strategies in light of these multi-state settlements, which underscore continued regulatory scrutiny of generic drug manufacturers for anti-competitive practices and potential liabilities.

Nebraska Attorney General Mike Hilgers has initiated a process to secure court endorsement for three distinct settlement agreements. These agreements involve generic drug manufacturers Ascend Laboratories, Citron Pharma (which has ceased operations), and Mayne Pharma, and are designed to resolve accusations of widespread anti-competitive behavior. On Thursday, October 8, 2026, from Lincoln, Attorney General Hilgers announced his participation in a coalition comprising 45 states and territories, all collectively pursuing these resolutions.

The core of the allegations against these pharmaceutical companies centers on a pervasive conspiracy to manipulate the market. Specifically, the manufacturers are accused of engaging in generic drug price fixing antitrust violations, which led to inflated prices for essential medications. Furthermore, the conspiracy aimed to deliberately limit competition within the generic drug sector, thereby harming consumers and the broader healthcare system. These settlements represent a significant step in addressing these long-standing drug manufacturer conspiracy allegations.

This multi-state action, spearheaded by Attorney General Hilgers and his counterparts, underscores a persistent and aggressive regulatory stance against anti-competitive practices within the pharmaceutical industry. The pursuit of settlements with Ascend, Citron, and Mayne Pharma is indicative of a broader trend where state attorneys general are actively collaborating to challenge alleged misconduct by generic drug manufacturers. Such multistate pharmaceutical antitrust efforts aim to restore fair market conditions and deter future illicit activities.

The legal framework underpinning these actions often involves state and federal antitrust laws designed to prevent monopolies, price fixing, and other forms of market manipulation. The allegations of a widespread conspiracy to inflate prices and limit competition fall squarely within the scope of these statutes. These cases serve as a critical reminder that generic drug companies, despite their role in providing affordable medications, are not exempt from stringent antitrust scrutiny, particularly when their actions are perceived to undermine market integrity.

The resolution of these cases through settlements with Ascend Laboratories, Citron Pharma, and Mayne Pharma carries substantial implications for both the pharmaceutical industry and the public. For consumers, the alleged generic drug price fixing antitrust scheme meant paying artificially high prices for necessary medications, directly impacting healthcare affordability and access. The successful pursuit of these settlements by Attorney General Hilgers and the coalition sends a clear message that such exploitative practices will be challenged vigorously.

Moreover, these settlements highlight the ongoing need for robust compliance and ethical conduct within the pharmaceutical sector. Compliance officers in the pharmaceutical industry should review their antitrust policies and pricing strategies in light of these multi-state settlements, which underscore continued regulatory scrutiny of generic drug manufacturers for anti-competitive practices and potential liabilities. The collective action by 45 states and territories against these drug manufacturer conspiracy allegations demonstrates the significant legal and reputational risks associated with engaging in market manipulation, reinforcing the importance of strict adherence to antitrust regulations to ensure fair competition and protect public welfare.

Compliance officers in the pharmaceutical industry should review their antitrust policies and pricing strategies in light of these multi-state settlements, which underscore continued regulatory scrutiny of generic drug manufacturers for anti-competitive practices and potential liabilities.

Source: Original reporting via state Attorney General's office.